Behar J, Biancani P
Gastroenterology. 1987 Mar;92(3):764-70. doi: 10.1016/0016-5085(87)90030-8.
The pharmacologic properties and specificity of cholecystokinin (CCK) receptors of the biliary tract were investigated by testing various sulfated and desulfated CCK fractions and by using specific CCK-gastrin antagonists. Sulfated CCK-7 (5-80 pmol/kg) caused gallbladder contraction and sphincter of Oddi relaxation. Denervation with tetrodotoxin decreased the gallbladder response by 50% and changed the sphincter of Oddi response from relaxation to contraction. Desulfated CCK-7 (80-400 pmol/kg) caused a weak gallbladder contraction that was unaffected by tetrodotoxin. The gallbladder did not respond to CCK-3 (10-80 nmol/kg) or to CCK-2 (10-160 nmol/kg) in doses that completely relaxed the sphincter of Oddi. These doses, however, were 5-2000 times higher than the maximal dose of sulfated CCK-7. After denervation with tetrodotoxin, desulfated CCK-7 (10-400 pmol/kg) induced a weak sphincter of Oddi contraction even with doses five times greater than the maximal dose of sulfated CCK-7. The denervated sphincter of Oddi did not respond to CCK-3 (10-80 nmol/kg) or CCK-2 (10-160 nmol/kg). Furthermore, a continuous proglumide infusion (5-20 mg/kg X min) and bolus doses of dibutyryl cyclic guanosine monophosphate (250-1000 micrograms/kg) blocked the effect of sulfated CCK-8 on the gallbladder and sphincter of Oddi. Higher doses of these antagonists were needed, however, to block the CCK effect on the sphincter of Oddi than on the gallbladder. In contrast, high doses of desulfated CCK-7 (100 pmol/kg) or CCK-3 (200 nmol/kg) did not antagonize the effect of sulfated CCK-8 (10-80 pmol/kg) on the gallbladder. These findings suggest the existence of three sets of specific CCK receptors with molecular configuration requirements determined by the type of cell where these receptors are located: on the postganglionic cholinergic neurons, on the smooth muscle cells of the gallbladder, and sphincter of Oddi, or on the postganglionic noncholinergic, nonadrenergic inhibitory neurons.
通过测试各种硫酸化和去硫酸化的胆囊收缩素(CCK)组分,并使用特异性CCK-胃泌素拮抗剂,对胆道CCK受体的药理特性和特异性进行了研究。硫酸化CCK-7(5 - 80 pmol/kg)可引起胆囊收缩和Oddi括约肌松弛。用河豚毒素去神经支配使胆囊反应降低50%,并使Oddi括约肌反应从松弛变为收缩。去硫酸化CCK-7(80 - 400 pmol/kg)引起微弱的胆囊收缩,不受河豚毒素影响。胆囊对CCK-3(10 - 80 nmol/kg)或CCK-2(10 - 160 nmol/kg)无反应,而这些剂量可使Oddi括约肌完全松弛。然而,这些剂量比硫酸化CCK-7的最大剂量高5 - 2000倍。用河豚毒素去神经支配后,即使去硫酸化CCK-7的剂量比硫酸化CCK-7的最大剂量大5倍,其(10 - 400 pmol/kg)仍可诱导Oddi括约肌微弱收缩。去神经支配的Oddi括约肌对CCK-3(10 - 80 nmol/kg)或CCK-2(10 - 160 nmol/kg)无反应。此外,持续输注丙谷胺(5 - 20 mg/kg·min)和大剂量注射二丁酰环磷酸鸟苷(250 - 1000 μg/kg)可阻断硫酸化CCK-8对胆囊和Oddi括约肌的作用。然而,阻断CCK对Oddi括约肌的作用所需的这些拮抗剂剂量比对胆囊的作用剂量更高。相比之下,高剂量的去硫酸化CCK-7(100 pmol/kg)或CCK-3(200 nmol/kg)并不拮抗硫酸化CCK-8(10 - 80 pmol/kg)对胆囊的作用。这些发现提示存在三组特异性CCK受体,其分子构型要求由这些受体所在细胞的类型决定:节后胆碱能神经元上、胆囊平滑肌细胞和Oddi括约肌上,或节后非胆碱能、非肾上腺素能抑制性神经元上。